Abstract
Urticaria is a common pediatric skin disorder. Histamine H1-receptor antagonists are effective in chronic as well as acute urticaria. When H1-anti-histamines are ineffective, add-on use of H2-receptor antagonists is thought to give better symptom relief. However, there are few reports on the therapeutic efficacy in pediatric patients. We retrospectively reviewed the medical records of pediatric patients with chronic spontaneous urticaria (csU) who met the following criteria. They were consulted our outpatient clinic between April 2010 and March 2012; were unsuccessfully treated with H1 antihistamines; and were treated with add-on H2-receptor antagonist (famotidine). In six patients who met the inclusion criteria (mean age 6.1 ± 5.1 years), urticaria activity score was significantly decreased from 4.3 ± 0.8 just before administration of famotidine to 1.3 ± 1.0 on the first outpatient visit within 4 weeks after the first administration of famotidine (p
Highlights
Urticaria is a fairly common skin disorder in children and is characterized by transient, pruritic, variably sized wheals with well-defined borders and central pallor
We retrospectively reviewed the medical records of pediatric patients with chronic spontaneous urticaria who met the following criteria
According to the patients’ mothers, every patient in this study achieved symptomatic relief such as improvement of itch and reduction of both area and number of hives within a few days after the beginning of famotidine administration, which strongly suggest that famotidine produced clinical improvement of chronic spontaneous urticaria (csU) rather than csU spontaneously resolved
Summary
Urticaria is a fairly common skin disorder in children and is characterized by transient, pruritic, variably sized wheals with well-defined borders and central pallor. Regarding recent reviews on pediatric chronic urticaria, one put H2-receptor antagonists collectively in the same category with first- and second-generation H1receptor antagonists as anti-histamines [1], and the other treated them as second-line drugs such as LTRA and ciclosporin [12]. These recommendations about the use of H2-receptor antagonists were based on experiences in adult rather than pediatric patients with csU. Takatsuka et al / Open Journal of Pediatrics 3 (2013) 20-23 antagonist, famotidine, in the past two years
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
